123 related articles for article (PubMed ID: 38662983)
21. Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations.
Goldstein AM; Landi MT; Tsang S; Fraser MC; Munroe DJ; Tucker MA
Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2208-12. PubMed ID: 16172233
[TBL] [Abstract][Full Text] [Related]
22. Pigmentary Markers in Danes--Associations with Quantitative Skin Colour, Nevi Count, Familial Atypical Multiple-Mole, and Melanoma Syndrome.
Johansen P; Andersen JD; Madsen LN; Ullum H; Glud M; Børsting C; Gniadecki R; Morling N
PLoS One; 2016; 11(3):e0150381. PubMed ID: 26938746
[TBL] [Abstract][Full Text] [Related]
23. Does MC1R genotype convey information about melanoma risk beyond risk phenotypes?
Kanetsky PA; Panossian S; Elder DE; Guerry D; Ming ME; Schuchter L; Rebbeck TR
Cancer; 2010 May; 116(10):2416-28. PubMed ID: 20301115
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and characterization of a melanoma-targeted fluorescence imaging probe by conjugation of a melanocortin 1 receptor (MC1R) specific ligand.
Tafreshi NK; Huang X; Moberg VE; Barkey NM; Sondak VK; Tian H; Morse DL; Vagner J
Bioconjug Chem; 2012 Dec; 23(12):2451-9. PubMed ID: 23116461
[TBL] [Abstract][Full Text] [Related]
25. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.
Demenais F; Mohamdi H; Chaudru V; Goldstein AM; Newton Bishop JA; Bishop DT; Kanetsky PA; Hayward NK; Gillanders E; Elder DE; Avril MF; Azizi E; van Belle P; Bergman W; Bianchi-Scarrà G; Bressac-de Paillerets B; Calista D; Carrera C; Hansson J; Harland M; Hogg D; Höiom V; Holland EA; Ingvar C; Landi MT; Lang JM; Mackie RM; Mann GJ; Ming ME; Njauw CJ; Olsson H; Palmer J; Pastorino L; Puig S; Randerson-Moor J; Stark M; Tsao H; Tucker MA; van der Velden P; Yang XR; Gruis N;
J Natl Cancer Inst; 2010 Oct; 102(20):1568-83. PubMed ID: 20876876
[TBL] [Abstract][Full Text] [Related]
26. CDKN2A and MC1R variants influence dermoscopic and confocal features of benign melanocytic lesions in multiple melanoma patients.
Bassoli S; Maurichi A; Rodolfo M; Casari A; Frigerio S; Pupelli G; Farnetani F; Pelosi G; Santinami M; Pellacani G
Exp Dermatol; 2013 Jun; 22(6):411-6. PubMed ID: 23711066
[TBL] [Abstract][Full Text] [Related]
27. Dermoscopic features of cutaneous melanoma are associated with clinical characteristics of patients and tumours and with MC1R genotype.
Fargnoli MC; Sera F; Suppa M; Piccolo D; Landi MT; Chiarugi A; Pellegrini C; Seidenari S; Peris K
J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1768-75. PubMed ID: 24588892
[TBL] [Abstract][Full Text] [Related]
28. MC1R germline variants confer risk for BRAF-mutant melanoma.
Landi MT; Bauer J; Pfeiffer RM; Elder DE; Hulley B; Minghetti P; Calista D; Kanetsky PA; Pinkel D; Bastian BC
Science; 2006 Jul; 313(5786):521-2. PubMed ID: 16809487
[TBL] [Abstract][Full Text] [Related]
29. IMP-3 is a novel progression marker in malignant melanoma.
Pryor JG; Bourne PA; Yang Q; Spaulding BO; Scott GA; Xu H
Mod Pathol; 2008 Apr; 21(4):431-7. PubMed ID: 18204432
[TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics of patients with cutaneous melanoma according to variants in the melanocortin 1 receptor gene.
Peña-Vilabelda MM; García-Casado Z; Requena C; Traves V; López-Guerrero JA; Guillén C; Kumar R; Nagore E
Actas Dermosifiliogr; 2014 Mar; 105(2):159-71. PubMed ID: 24238329
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for keratinocyte skin cancer in patients diagnosed with melanoma, a large retrospective study.
Espinosa P; Pfeiffer RM; García-Casado Z; Requena C; Landi MT; Kumar R; Nagore E
Eur J Cancer; 2016 Jan; 53():115-24. PubMed ID: 26702765
[TBL] [Abstract][Full Text] [Related]
32. High naevus count and MC1R red hair alleles contribute synergistically to increased melanoma risk.
Duffy DL; Lee KJ; Jagirdar K; Pflugfelder A; Stark MS; McMeniman EK; Soyer HP; Sturm RA
Br J Dermatol; 2019 Nov; 181(5):1009-1016. PubMed ID: 30820946
[TBL] [Abstract][Full Text] [Related]
33. Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries.
Goldstein AM; Chaudru V; Ghiorzo P; Badenas C; Malvehy J; Pastorino L; Laud K; Hulley B; Avril MF; Puig-Butille JA; Miniere A; Marti R; Chompret A; Cuellar F; Kolm I; Mila M; Tucker MA; Demenais F; Bianchi-Scarra G; Puig S; de-Paillerets BB
Int J Cancer; 2007 Aug; 121(4):825-31. PubMed ID: 17397031
[TBL] [Abstract][Full Text] [Related]
34. MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation.
García-Borrón JC; Abdel-Malek Z; Jiménez-Cervantes C
Pigment Cell Melanoma Res; 2014 Sep; 27(5):699-720. PubMed ID: 24807163
[TBL] [Abstract][Full Text] [Related]
35. Germline variation of the melanocortin-1 receptor does not explain shared risk for melanoma and thyroid cancer.
Bauer J; Weng J; Kebebew E; Soares P; Trovisco V; Bastian BC
Exp Dermatol; 2009 Jun; 18(6):548-52. PubMed ID: 19493000
[TBL] [Abstract][Full Text] [Related]
36. Dermoscopic features of melanomas associated with MC1R variants in Spanish CDKN2A mutation carriers.
Cuéllar F; Puig S; Kolm I; Puig-Butille J; Zaballos P; Martí-Laborda R; Badenas C; Malvehy J
Br J Dermatol; 2009 Jan; 160(1):48-53. PubMed ID: 18795926
[TBL] [Abstract][Full Text] [Related]
37. In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma.
Tafreshi NK; Silva A; Estrella VC; McCardle TW; Chen T; Jeune-Smith Y; Lloyd MC; Enkemann SA; Smalley KS; Sondak VK; Vagner J; Morse DL
Mol Pharm; 2013 Aug; 10(8):3175-85. PubMed ID: 23763620
[TBL] [Abstract][Full Text] [Related]
38. Sporadic melanoma in South-Eastern Italy: the impact of melanocortin 1 receptor (MC1R) polymorphism analysis in low-risk people and report of three novel variants.
Guida S; Bartolomeo N; Zanna PT; Grieco C; Maida I; De Summa S; Tommasi S; Guida M; Azzariti A; Foti C; Filotico R; Guida G
Arch Dermatol Res; 2015 Aug; 307(6):495-503. PubMed ID: 25736238
[TBL] [Abstract][Full Text] [Related]
39. MC1R variants increase risk of melanomas harboring BRAF mutations.
Fargnoli MC; Pike K; Pfeiffer RM; Tsang S; Rozenblum E; Munroe DJ; Golubeva Y; Calista D; Seidenari S; Massi D; Carli P; Bauer J; Elder DE; Bastian BC; Peris K; Landi MT
J Invest Dermatol; 2008 Oct; 128(10):2485-90. PubMed ID: 18368129
[TBL] [Abstract][Full Text] [Related]
40. Melanoma risk associated with MC1R gene variants in Latvia and the functional analysis of rare variants.
Ozola A; Azarjana K; Doniņa S; Proboka G; Mandrika I; Petrovska R; Cēma I; Heisele O; Eņģele L; Streinerte B; Pjanova D
Cancer Genet; 2013 Mar; 206(3):81-91. PubMed ID: 23522749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
